- Home
- INTS vs GABC Comparison
INTS vs GABC Comparison
Compare INTS & GABC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- GABC
- Stock Information
- Founded
- INTS 2012
- GABC 1910
- Country
- INTS United States
- GABC United States
- Employees
- INTS 16
- GABC N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- GABC Major Banks
- Sector
- INTS Health Care
- GABC Finance
- Exchange
- INTS Nasdaq
- GABC Nasdaq
- Market Cap
- INTS 30.8M
- GABC N/A
- IPO Year
- INTS 2023
- GABC N/A
- Fundamental
- Price
- INTS $2.06
- GABC $37.46
- Analyst Decision
- INTS Strong Buy
- GABC Buy
- Analyst Count
- INTS 3
- GABC 4
- Target Price
- INTS $8.50
- GABC $46.00
- AVG Volume (30 Days)
- INTS 38.4K
- GABC 138.6K
- Earning Date
- INTS 03-13-2025
- GABC 04-28-2025
- Dividend Yield
- INTS N/A
- GABC 3.09%
- EPS Growth
- INTS N/A
- GABC N/A
- EPS
- INTS N/A
- GABC 2.83
- Revenue
- INTS N/A
- GABC $250,476,000.00
- Revenue This Year
- INTS N/A
- GABC $43.16
- Revenue Next Year
- INTS N/A
- GABC $7.60
- P/E Ratio
- INTS N/A
- GABC $13.27
- Revenue Growth
- INTS N/A
- GABC 0.94
- 52 Week Low
- INTS $1.50
- GABC $31.06
- 52 Week High
- INTS $5.28
- GABC $47.08
- Technical
- Relative Strength Index (RSI)
- INTS 46.37
- GABC 34.25
- Support Level
- INTS $1.88
- GABC $37.89
- Resistance Level
- INTS $2.18
- GABC $38.60
- Average True Range (ATR)
- INTS 0.21
- GABC 0.75
- MACD
- INTS -0.01
- GABC -0.05
- Stochastic Oscillator
- INTS 39.73
- GABC 0.47
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.